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Abstract 
Background:  
The relevance of lysophosphatidylcholine acyltransferase1 (LPCAT1), a cytosolic enzyme in 
the remodeling pathway of phosphatidylcholine metabolism, in oral squamous cell carcinoma 
(OSCC) is unknown. We investigated LPCAT1 expression and its functional mechanism in 
OSCCs. 
 
Methods:  
We analyzed LPCAT1 mRNA and protein expression levels in OSCC-derived cell lines. 
Immunohistochemistry was performed to identify correlations between LPCAT1 expression 
levels and primary OSCCs clinicopathological status. We established LPCAT1 knockdown 
models of the OSCC-derived cell lines (SAS, Ca9-22) for functional analysis and examined the 
association between LPCAT1 expression and the platelet-activating factor (PAF) concentration 
and PAF-receptor (PAFR) expression.   
 
Results:  
LPCAT1 mRNA and protein were up-regulated significantly (p<0.05) in OSCC-derived cell 
lines compared with human normal oral keratinocytes. Immunohistochemistry showed 
significantly (p<0.05) elevated LPCAT1 expression in primary OSCCs compared with normal 
counterparts and a strong correlation between LPCAT1-positive OSCCs and tumoral size and 
regional lymph node metastasis. In LPCAT1 knockdown cells, cellular proliferation and 
invasiveness decreased significantly (p<0.05); cellular migration was inhibited compared with 
control cells. Down-regulation of LPCAT1 resulted in a decreased intercellular PAF 
concentration and PAFR expression. 
 
Conclusion:  
LPCAT1 was overexpressed in OSCCs and correlated with cellular invasiveness and migration. 
LPCAT1 may contribute to tumoral growth and metastasis in oral cancer.   
  
Introduction 
Lysophosphatidylcholine acyltransferase1 (LPCAT1) is a cytosolic enzyme that catalyzes the 
conversion of lysophosphatidylcholine (LPC) to phosphatidylcholine (PC) in remodeling the 
pathway of PC biosynthesis. LPCAT1 is expressed constantly in lung tissue, especially in type 
II alveolar cells, and plays a fundamental role in generating dipalmitoyl-PC of pulmonary 
surfactant [1]. To date, LPCAT1 overexpression has been reported in hepatocellular carcinoma 
[2], colorectal adenocarcinoma [3], and prostate cancer [4-6] and has been described as 
contributing to cancer progression, metastasis, and recurrence. We previously reported the gene 
expression profile of OSCC to identify cancer-related genes, and LPCAT was up-regulated in 
OSCC-derived cell lines [7]. Recently, LPCAT1 was found catalyzing the biosynthesis of 
platelet-activating factor (PAF) (1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) with its 
lyso-PAF acetyltransferase activity [8, 9]. 
PAF is a lipid mediator involved in numerous biologic responses, including platelet 
activation, airway construction, and hypotension [9]. In the normal state, PAF is conditioned in 
very low concentrations, but in cases with some types of stimulation such as inflammation, PAF 
is produced immediately in several cellular types such as leukocytes, platelets, macrophages, 
and endothelial and renal cells [10, 11]. PAF is biosynthesized through two independent 
pathways called the de novo and remodeling pathways by lyso-PAF acetyltransferase [8]. There 
are two lyso-PAF acetyltransferases, LPCAT1 and LPCAT2, both of which produce PAF via 
remodeling pathway. LPCAT2 is the first detected lyso-PAF acetyltransferase 
 that catalyzes PAF biosynthesis in inflammatory cells such as macrophages, leukocytes, 
and neutrophils. This enzyme is Ca2+ dependent and activated in response to lipopolysaccharide 
or Toll-like receptor stimulation. In contrast, LPCAT1, recently recognized as another lyso-PAF 
acetyltransferase, is predominantly expressed in lung tissue and its activity is Ca2+ independent. 
Moreover, LPCAT1 is neither activated nor up-regulated by inflammatory stimulation. Thus, 
LPCAT1 have been thought to be non-inflammatory/constitutive lyso-PAF acetyltransferase. 
However, the role of PAF constitutively produced by LPCAT1 was still unknown.  
When cells are exposed to PAF, it binds to a specific receptor, PAF receptor (PAFR), 
which has restricted expression in key target cells of the inflammatory, immune, and hemostatic 
systems [12, 13]. PAFR belongs to the G protein-coupled receptor protein family, and activated 
tyrosine kinase transduces cellular signals via Erk [14], Janus kinase 2 [15], RhoA, p38MAPK 
[16], and other mediators. Activation of the PAF/PAFR pathway induces cellular proliferation 
in human epithelial cells, skin fibroblasts [17], and pulmonary vascular smooth cell [18]. 
Recently, numerous studies have evaluated the relation between PAF/PAFR and carcinogenesis 
and tumoral malignancies and reported some essential effects of PAF in the tumoral 
microenvironment [19]. 
In the current study, LPCAT1 was overexpressed in OSCC-derived cell lines and primary 
OSCCs. We also analyzed the correlation between LPCAT1 expression and clinicopathological 
characteristics. Furthermore, we assumed that LPCAT1 affects the functional characteristics of 
OSCC via PAF production and performed functional analysis to define the biologic effects and 
molecular mechanism of LPCAT1.   
 
MATERIALS AND METHODS 
Ethical statement.  
The Ethical Committee of the Graduate School of Medicine, Chiba University approved the 
study protocol (approval number, 236), which was performed in accordance with the ethical 
standards of the Declaration of Helsinki. All patients provided written informed consent. 
 
OSCC-derived cell lines and tissue samples.  
RIKEN (Ibaraki, Japan) provided the Sa3, HO-1-u-1, KOSC-2, Ca9-22, HO-1-N-1, HSC-2, and 
HSC-3 cell lines through the National Bio-Resource Project of the Ministry of Education, 
Culture, Sports, Science and Technology, Tokyo, Japan. Short tandem repeat profiles confirmed 
the cellular identity. All OSCC-derived cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum 
(FBS) (Sigma) and 50 units/ml of penicillin and streptomycin (Sigma). Primary cultured human 
normal oral keratinocytes (HNOKs) were used as normal controls [20, 21]. The HNOKs were 
healthy oral mucosal epithelial specimens collected from young patients aged 22-34 at Chiba 
University Hospital. These independent HNOKs were primary cultured and maintained in 
Keratinocyte-SFM (Gibco, Life Technologies, Carlsbad, CA, USA) comprised of 5 ml of oral 
keratinocyte growth supplement (ScienCell Research Laboratories, Carlsbad, CA, USA) and 
5ml of penicillin/streptomycin solution (ScienCell Research Laboratories).  
Fifty-five pairs of primary OSCCs samples and corresponding normal oral epithelial 
tissues were obtained intraoperatively at Chiba University Hospital. The resected tissues were 
divided for RNA isolation and immunohistochemistry (IHC); the former tissues were frozen 
immediately and stored at -80°C, the latter tissues were fixed in 20% buffered formaldehyde 
solution. Each tissue specimen was diagnosed histopathologically according to the World 
Health Organization criteria by the tumor-node-metastases classification of the International 
Union against Cancer. All OSCC samples were confirmed histologically that tumor was present 
in over 90% of the specimens. 
 
Preparation of cDNA and protein.  
Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), according to 
the manufacturer’s instructions. cDNA was generated from 1 µg of total RNA using ReverTra 
Ace (TOYOBO CO., LTD., Osaka, Japan), according to the instruction manual. The cells were 
washed twice with cold phosphate-buffered saline (PBS) and centrifuged briefly. The cell 
pellets were incubated at 4°C for 30 min in a lysis buffer (7 M urea, 2 M thiourea, 4% [w/v] 
CHAPS, and 10 mM Tris, pH 7.4) with a proteinase inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany). The protein concentration was measured using a commercial Bradford 
reagent (BioRad, Richmond, CA, USA). 
 
mRNA expression analysis.  
Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was 
performed to evaluate the expression level of the target gene (LPCAT1) in the OSCC-derived 
cell lines and HNOKs. qRT-PCR was performed with one method using LightCycler 480 
Probes Master kit (Roche Diagnostics). Primers were designated using the ProbeFinder qPCR 
assay design software accessible at the Universal ProbeLibrary 
(http://qpcr.probefinder.com/roche3.html). The nucleotide sequences of gene-specific primers 
for qRT-PCR amplification were used: LPCAT1, forward, 
5’-CACAACCAAGTGGAAATCGAG-3’; and reverse 5’-GCACGTTGCTGGCATACA-3’, 
(universal probe #35). All qRT-PCR analyses were performed using the LightCycler 480 PCR 
system (Roche Diagnostics). The reaction mixture was loaded onto a PCR plate and subjected to 
an initial denaturation at 95°C for 10 minutes, followed by 60 cycles of amplification, at 95°C 
for 10 seconds for denaturation, at 60°C for 30 seconds for primer annealing, and 72°C for 1 
second for extension, followed by a cooling step at 50°C for 30 seconds. The transcript amounts 
for the target genes were estimated from the respective standard curves and normalized to the 
glyceraldehyde-3-phospate dehydrogenase (GAPDH, forward, 
5’-CATCTCTGCCCCCTCTGCTGA-3’; reverse, 5’-GGATGACCTTGCCCACAGCCT-3’; 
and universal probe #60). The transcript amount for LPCAT1 was estimated from the respective 
standard curves and normalized with the GAPDH transcript amount determined in 
corresponding samples. 
 
Immunoblot analysis.  
Protein extracts (20 µg) were electrophoresed in 4-12% Bis-Tris gel (Invitrogen), transferred to 
polyvinylidene difluoride membranes (Invitrogen), and blocked for 1 hour at room temperature 
in Blocking One (Nacalai Tesque Kyoto, Japan). The membrane were washed three times with 
0.1% Tween-20 in Tris-buffered saline and incubated with 1.0 µg/ml affinity-purified rabbit 
anti-human LPCAT1 polyclonal antibody (Proteintech, Chicago, IL, USA) (1:1000 dilution in 
TBS-T), and goat anti-PAFR polyclonal antibody (Santa Cruz Biotechnology. Inc., CA, USA) 
(1:100 dilution in TBS-T) overnight at 4°C. The membranes were washed with 0.1% Tween20 
in Tris-buffered saline and incubated with a secondary antibody and coupled to horseradish 
peroxidase-conjugated anti-rabbit or anti-goat IgG (Promega, Madison, WI, USA) for 1 hour at 
room temperature. Finally, the membranes were detected using SuperSignal West Pico 
Chemiluminescent substrate (Thermo Fischer Scientific, Rockford, IL, USA) and 
immunoblotting was visualized by exposing the membranes to ATTO Light-Capture II (ATTO, 
Tokyo, Japan). Signal intensities were quantitated using the CS Analyzer version 3.0 software 
(ATTO). Densitometric LPCAT1 protein data were normalized to GAPDH protein levels. 
 
IHC.  
IHC was performed on 4-µm sections of paraffin-embedded specimens using rabbit 
anti-LPCAT1 polyclonal antibody (Proteintech) or anti-LPCAT2 polyclonal antibody (Santa 
Cruz Biotechnology). Briefly, after deparaffinization and hydration, the endogenous peroxidase 
activity was quenched by a 30-minute incubation in a mixture of 3% hydrogen peroxide 
solution (diluted in distilled water), after which the sections were blocked for 1 hour at room 
temperature with 1.0% bovine serum albumin in PBS before reaction overnight with anti 
LPCAT1 antibody at 4°C in a moist chamber. Upon incubation with the primary antibody, the 
specimens were washed three times with PBS and treated with Envision reagent (DAKO, 
Carpentaria, CA, USA) or HRP-rabelled rabbit anti-goat IgG polycronal antibody (Abcam Ltd. 
Cambridge UK ) followed by color development in 3,3’-diaminobenzine tetrahydrochloride 
(DAKO). The slides then were counterstained lightly with hematoxylin, dehydrated with 
ethanol, cleaned with xylene, and mounted with Malinol (Muto Pure Chemicals Co., Tokyo, 
Japan). In order to confirm the reaction of antibody, we stained mouse lung tissues and mouse 
pancreatic tissue as positive controls for LPCAT1 and LPCAT2 respectively. While, 
non-specific bindings of an antibody to proteins other than the antigen sometimes occurred. As 
a negative control, the slides were immunostained without exposure to primary antibodies, 
which confirmed the staining specificity. To quantify the status of the LPCAT1 protein 
expression in those components, we used an IHC scoring system described previously [22-26]. 
This scoring system was established for semiquantitative evaluation of IHC staining. The 
intensities of the LPCAT1 immunoreaction in the cell were scored as follows: 1+, weak; 2+, 
moderate; and 3+, intense. The cellular numbers and the staining intensities then were 
multiplied to produce a LPCAT1 IHC score. Cases with a LPCAT1 IHC score exceeding 61.8 
(+3 standard deviation [SD] score for normal tissue) were defined as LPCAT1-positive. The 
±3-SD cutoff, which statistically is just 0.2% of the measurement and is expected to fall outside 
this range, was used because it was unlikely to be affected by a random experimental error 
produced by a sample manipulation [27]. Two independent pathologists, neither of whom had 
knowledge of the patients’ clinical status, made these judgments. 
 
 
Transfection with shRNA plasmid.  
OSCC-derived cells (SAS and Ca9-22) were stably transfected with the LPCAT1 shRNA 
(shLPCAT1, Santa Cruz Biotechnology) or the control shRNA (shMock, Santa Cruz 
Biotechnology) construct by Lipofectamine LTX and Plus Reagents (Invitrogen). After 
transfection, the stable transfectants were isolated by a culture medium containing 2µg/ml of 
Puromycin (Invitrogen). Two to three weeks after transfection, viable colonies were transferred 
to new dishes. shLPCAT1- and shMock-transfected cells were used for further experiments. 
 
Proliferation assay.  
To evaluate the effect of LPCAT1 knockdown on cellular proliferation, we analyzed cellular 
growth in shLPCAT1- and shMock-transfected cells. These transfectants were seeded in 6-cm 
dishes at a density of 1×104 viable cells per dishes. The experiments were carried out for 192 
hours by counting the cells every 24 hours. At the indicated time points, the cells were 
trypsinized and counted using a hemocytometer in triplicate samples. We compared the 
numbers of the shLPCAT1- and shMock-transfected cells. 
 
Invasiveness assay.  
To evaluate the effect of LPCAT1 knockdown on invasiveness, a total of 2.5×105 cells 
resuspended in the serum-free medium were seeded on a 0.8-µm polyethylene terephthalate 
membrane insert in a transwell apparatus (Becton-Dickinson Labware, Franklin Lakes, NJ, 
USA). In the lower chamber, 2 ml of DMEM with 10% FBS was added as a chemoattractant. 
After the cells were incubated for 48 hours at 37°C, the insert was washed with PBS, and the 
cells on the top surface of the insert were removed with cotton swabs. Cells adhering to the 
lower surface of the membrane were fixed with methanol and stained with crystal violet. The 
number of cells that invaded through the pores in five random fields was counted using a light 
microscope at ×100 magnification. 
 
Wound healing assay.  
To evaluate the effect of LPCAT1 knockdown on migration, we performed a wound healing 
assay as described previously [28, 29]. Briefly, after uniform wounds were made in confluent 
culture of shLPCAT1- and shMock-transfected cells, the extent of closure was monitored 
visually every 3 hours for 24 hours. The results were visualized by measuring the wound spaces 
using the Lenaraf220 software (http://www.vector.co.jp/soft/dl/win95/art/se312811.html). The 
mean value was calculated from data from three separate chambers. 
 
ELISA of PAF.  
To assess the effect of LPCAT1 knockdown on PAF production, we performed an 
enzyme-linked immunosorbent assay (ELISA) on PAF using an ELISA kit for PAF 
(Cloud-Clone Corp, Houston, TX, USA), according to the instruction manual with some 
modification. Briefly, after cells were cultured to confluence in serum-supplemented DMEM 
and washed three times with ice-cold PBS and then scraped off. The harvested cells were 
diluted with 500 µl of PBS and the cellular membranes were broken by a freezing and thawing 
method. The cellular lysates were centrifuged for 5 minutes at 5,000 g in 4°C, and the collected 
supernatants were assayed. This ELISA kit used the competitive inhibition enzyme technique, 
and absorbance at 450 nm was determined with microplate reader (Benchmark Plus, Bio-Rad, 
Hercules, CA, USA). To standardize the values, we used a protein concentration of samples as 
an internal control.  
 
Statistical analysis.  
All statistical analyses were performed using the Microsoft Excel (Microsoft, Redmond, WA, 
USA). The statistical significance of the LPCAT1 expression levels was evaluated using the 
Mann-Whitney U-test. Fischer’s exact tests were used to compare categorical variables. All 
tests were two-sided. P<0.05 was considered statistically significant. The data are expressed as 
the mean ±standard error of the mean. 
 
Results 
LPCAT1 mRNA and protein up-regulation in OSCC-derived cell 
lines.  
To analyze the LPCAT1 expression status, we performed qRT-PCR and immunoblotting 
analysis using OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, Ca9-22, KOSC2, SAS, Sa3, 
HO-1-u1, and HO-1-N1) and HNOKs. LPCAT1 mRNA was significantly (p<0.05) up-regulated 
in almost all OSCC-derived cell lines except for KOSC2 compared with the HNOKs (Fig. 1A). 
Fig. 1B shows representative results of immunoblotting analysis of LPCAT1 protein expression 
compared with the HNOKs. A significant increase in LPCAT1 protein expression was seen in 
all OSCC-derived cell lines compared with the HNOKs. Expression analysis indicated that 
translational products of this molecule were highly expressed in OSCC-derived cell lines.  
Fig. 1. Expression profiles of LPCAT1 in OSCC-derived cell lines and OSCC samples. (A) 
Quantification of LPCAT1 mRNA levels in OSCC-derived cell lines by qRT-PCR analysis. To 
determine the mRNA expression status of LPCAT1, we performed qRT-PCR analysis using 9 
OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, Sa3, SAS, Ca9-22, KOSC2, HO-1-N-1, and 
HO-1-u-1), and HNOKs. LPCAT1 mRNA is significantly up-regulated in the nine OSCC-derived cell 
lines compared with the HNOKs. The data are expressed as the mean ±SEM of values from three 
assays (*p<0.05, Mann-Whitney U test). (B) Immunoblot analysis of LPCAT1 in the OSCC-derived 
cells lines and HNOKs. To investigate the protein expression status of LPCAT1, we performed 
immunoblot analysis in the same OSCC-derived cell lines and HNOKs. The LPCAT1 protein 
expression level is significantly up-regulated in all OSCC-derived cell lines compared with the 
HNOKs. Densitometric LPCAT1 protein data are normalized to the GAPDH protein levels. The 
values are expressed as a percentage of the HNOKs. (C) IHC of LPCAT1 on primary OSCC samples. 
Representative IHC results are shown for LPCAT1 protein in normal oral tissue (a, b) and primary 
OSCCs (c, d). The original magnifications are 100×(a, c), and 400×(b, d). Strong LPCAT1 
immunoreactivity is detected in the primary OSCCs. (D) The status of LPCAT1 protein expression in 
primary OSCCs (n=55) and the normal counterparts. The LPCAT1 IHC scores are calculated as 
follows: IHC score = 1×(number of weakly stained cells in the field) + 2×(number of moderately 
stained cells in the field) + 3×(number of intensely stained cells in the fields). The LPCAT1 IHC 
scores for normal oral tissues range from 0.5 to 68.5 and that of primary OSCCs range from 23.7 to 
205.9. The LPCAT1 protein expression levels in OSCCs are significantly (*p<0.01, Mann-Whitney U 
test) higher than those in normal oral tissues.  
 
Overexpression of LPCAT1 in primary OSCCs. To determine the LPCAT1 expression status 
in primary OSCCs and its relevance to the clinicopathological characteristics, we analyzed the 
LPCAT1 protein expression in primary OSCCs and paired normal oral tissues from 55 patients 
using the IHC scoring system. We also examined IHC for LPCAT2 protein expression in 
primary OSCCs, but there was no significant immunoreaction (Supplementary Fig. 1). Fig. 1C 
shows representative IHC results for LPCAT1 protein in normal oral tissues and primary 
OSCCs. Strong LPCAT1 immunoreactivity was detected in the cytoplasm in the OSCCs 
(Fig.1C: c, d), while the normal tissues showed negative immunostaining (Fig. 1C: a, b). The 
LPCAT1 IHC scores ranged from 23.7 to 205.9 in OSCCs (median, 84.5) and from 0.5 to 68.5 
in normal counterparts (median, 15.17). The IHC scores in primary OSCCs were significantly 
(p<0.05) higher than those in the normal oral tissues (Fig. 1D). After statistical analysis, 36 
(65%) of 55 OSCC samples were considered LPCAT1-positive. We then analyzed the 
correlations between the clinicopathological characteristics of the patients with OSCC and the 
status of the LPCAT1 protein expression using the IHC scoring system (Table 1). Among the 
clinical classifications, the LPCAT1-positive OSCCs were correlated significantly (p<0.05 for 
all comparisons) with larger tumors, frequent regional lymph node metastasis, and advanced 
clinical stages. No significant relations were found with age, gender, histopathological type, or 
tumoral site. 
  
Table 1.  Correlation between clinicopathological parameters of patients with OSCC and LPCAT1 
protein expression 
 Result of immunostaining Parameter No. of patients/ (%)  
 Total LPCAT1(–)
（−） 
LPCAT1(+) p value 
Age at surgery (year)       
＜60 14 4 (29%) 10 (71%) 0.816 
60～70 16 5 (31%) 11 (69%)  
＞70 25 10 (40%) 15 (60%)  Gender       Male 34 11 (32%) 23 (68%) 0.663 
Female 21 8 (38%) 13 (62%)  T-primary tumor       1 2 1 (50%) 1 (50%) 0.005 * 
2 34 17 (50%) 17 (50%)  3 11 1 (9%) 10 (91%)  4 8 0 (0%) 8 (100%)  N-regional lymph node       – 32 16 (50%) 16 (50%) 0.009 * 
+ 23 3 (13%) 20 (87%)  Stage       Ⅰ 2 1 (50%) 1 (50%) 0.001 * 
Ⅱ 24 14 (58%) 10 (42%)  Ⅲ 11 3 (27%) 8 (73%)  Ⅳ 18 1 (6%) 17 (94%)  Histopathologic type       Well 37 12 (32%) 25 (68%) 0.811 
Moderate 14 5 (36%) 9 (64%)  Poor 4 2 (50%) 2 (50%)  Tumor site       Tongue 35 14 (40%) 21 (60%) 0.263 
Gingiva 15 2 (13%) 13 (87%)  Buccal mucosa 2 0 (0%) 2 (100%)  Soft palate 2 2 (100%) 0 (0%)  Oral floor 1 1 (100%) 0 (0%)  
* p<0.05  
Establishment of LPCAT1 knockdown cells.  
To investigate the LPCAT1 function in vitro, we established LPCAT1 knockdown cells using 
shRNA system. LPCAT1 shRNA (shLPCAT1) and the control shRNA (shMock) were 
transfected in the OSCC-derived cell lines, SAS and Ca9-22, respectively. The expression levels 
of LPCAT1 mRNA and protein in shLPCAT1-transfected cells were significantly (p<0.05) 
lower than those in shMock-transfected cells (Fig. 2A, B).  
 
Fig. 2. Establishment of shLPCAT1-transfected cells. (A) Expression of LPCAT1 mRNA in 
shMock- and shLPCAT1-transfected cells (SAS- and Ca9-22-derived transfectants). LPCAT1 mRNA 
expression in shLPCAT1-transfected cells is significantly (*p<0.05, Mann-Whitney U test) lower than 
in the shMock-transfected cells. (B) Immunoblot analysis of LPCAT1 protein in shMock- and 
shLPCAT1-transfected cells (SAS- and Ca9-22-derived transfectants). The LPCAT1 protein 
expression in shLPCAT1-transfected cells is decreased markedly compared with the 
shMock-transfected cells. 
 
Decreased cellular proliferation, migration, invasiveness in 
LPCAT1 knockdown cells.  
To investigate the effect of LPCAT1 on cellular proliferation, we monitored cellular growth for 
168 hours. SAS and Ca9-22 shLPCAT1-transfected cells had significant (p<0.05) decreases in 
cellular growth compared with the shMock-transfected cells (Fig. 3A, B). We also performed 
cellular migration and invasiveness assays to study the biologic effects of LPCAT1 in relation 
to metastatic capability. In a migration assay, when we visually monitored the area of uniform 
wounds in confluent cell culture, the wounds in the shLPCAT1-transfected cells closed later 
than those in the shMock-transfected cells in both cell lines (Fig. 3C, D). In the invasiveness 
assay, the number of penetrating shLPCAT1-transfected cells decreased compared with 
shMock-transfected cells (Fig. 3E, F). Therefore, shLPCAT1-transfected cells showed 
decreased migration and invasiveness capabilities. 
 
Fig. 3. Effect of LPCAT1 knockdown on OSCC-derived cell lines. (A, B) Proliferation assay of 
shMock- and shLPCAT1-transfected cells (SAS- and Ca9-22-derived transfectants). To determine the 
effect of shLPCAT1 on cellular proliferation, shLPCAT1- and shMock-transfected cells were seeded 
in 6-cm dishes at a density of 1×104 viable cells/well. Both transfected cells were counted on seven 
consecutive days. The cellular growth of shLPCAT1-transfected cells (SAS- and Ca9-22- derived 
transfectants) is inhibited significantly compared with the shMock-transfected cells after 5 days (120 
hours). The results are expressed as the mean ±SEM of values from three assays. The asterisks 
indicate significant (*p<0.05, Mann-Whitney U test) differences between the shLPCAT1- and 
shMock-transfected cells. (C, D) Migration assay of shMock- and shLPCAT1-transfected cells (SAS- 
and Ca9-22-derived transfectants). To evaluate the effect of LPCAT1 knockdown on migration, 
uniform wounds were made in confluent culture of the shLPCAT1- and shMock-transfected cells 
(SAS- and Ca9-22-derived transfectants) and the extent of closure was monitored visually every 3 
hours for 24 hours. The mean value was calculated from data obtained from three separate chambers. 
The wound area was decreased significantly (*p<0.05, Mann-Whitney U test) in the culture of 
shMock-transfected cells after 12 hours, whereas a gap remained in the shLPCAT1-transfected cells. 
(E, F) Invasiveness assay of shMock- and shLPCAT1-transfected cells (SAS- and Ca9-22-derived 
transfectants). To evaluate the effect of LPCAT1 knockdown on invasiveness, we seeded 2.5×105 
cells in the serum-free medium of a 0.8-µm polyethylene terephthalate membrane insert in a transwell 
apparatus and added serum-supplemented medium in the lower chamber as a chemoattractant. After 
incubation at 37°C for 48 hours, cells that penetrated through the pores were fixed, stained, and 
counted using a light microscope at ×100 magnification. The mean value was calculated from data 
obtained from three separate chambers. The number of shLPCAT1-transfected cells penetrating 
through the pores is decreased significantly (*p<0.05, Mann-Whitney U test) compared with the 
shMock-transfected cells. 
 
Knockdown of LPCAT1 and suppressed PAF synthesis and PAFR 
expression in OSCC-derived cell lines. 
 The biosynthesis of PAF has been studied extensively in various cells and tissues, and 
LPCAT1 catalyzed PAF biosynthesis [8]. Numerous studies also have been performed to 
investigate the effects of PAF on tumoral characteristics [19]. To explain the relation between 
overexpressed LPCAT1 and cancer malignancy, we investigated the intracellular PAF 
concentration. To determine the PAF concentrations in shLPCAT1- and shMock-transfected 
cells, ELISA was carried out using cell lysates. The results showed that the intracellular PAF 
concentration decreased significantly (p<0.05) in shLPCAT1-transfected cells compared with 
shMock-transfected cells (Fig. 4A). The levels of intracellular PAF were represented as the 
normalized index, which was standardized by protein concentration and calculated as the 
percentage of the PAF concentration relative to that in the shMock-transfected cells. 
PAF affects cellular function via binding to and activating PAFR, and PAFR is also 
overexpressed in response to PAF stimulation [19]. Considering these findings, we conducted 
further immunoblotting analysis on shLPCAT1- and shMock-transfected cells to detect the 
status of the PAFR expression. The results showed that LPCAT1 knockdown caused markedly 
decreased levels of PAFR protein expression (Fig. 4B). Thus, the intracellular PAF 
concentration and PAFR expression were down-regulated in shLPCAT1-transfected cells. 
 
Fig. 4. Reduced PAF synthesis and PAFR expression in shLPCAT1-transfected cells. (A) 
Evaluation of intracellular PAF concentration in shMock- and shLPCAT1-transfected cells (SAS- and 
Ca9-22-derived transfectants). To determine the intercellular PAF concentrations, we examined 
cellular lysates using ELISA and normalized with protein concentration. The mean value was 
calculated from the data obtained from three independent samples. The relative PAF concentration in 
the shLPCAT1-transfected cells is decreased significantly (*p<0.05, the Mann-Whitney U test) 
compared with the shMock-transfected cells. (B) Evaluation of PAFR expression in shMock- and 
shLPCAT1-transfected cells (SAS- and Ca9-22-derived transfectants). Immunoblot analysis shows 
that PAFR protein expression in the shLPCAT1-transfected cells is decreased markedly compared 
with the shMock-transfected cells. 
 
Discussion 
In the current study, we report here that LPCAT1 often is overexpressed in OSCC-derived cell 
lines and primary OSCC specimens. Moreover, LPCAT1 protein expression levels in primary 
OSCCs were correlated significantly (p<0.05) with tumoral size, regional lymph node 
metastasis, and clinical stages. Functional analysis using LPCAT1 knockdown cells showed that 
down-regulation of LPCAT1 repressed not only cellular proliferation but also invasiveness and 
migration. These findings supported the prospect that overexpressed LPCAT1 may contribute to 
tumoral growth and metastasis in OSCCs. Past studies have reported overexpressed LPCAT1 in 
cancers and mentioned the close interaction between overexpressed LPCAT1 and malignancies, 
such as vigorous tumoral growth, frequent metastasis, early recurrence, and poor prognosis 
[2-6]. However, the molecular mechanisms and detailed function of LPCAT1 in OSCC 
progression remained unclear. 
Xu et al. (2013) reported a relationship between LPCAT1 and PAF in prostatic cancers 
and suggested that PAF may play an important role in accelerating progression of aggressive 
phenotypes. PAF is a phospholipid mediator with pleotropic and potent biologic effects and 
functions through binding to and activating its specific receptor PAFR[30, 31]. Until now, PAF 
and PAFR were extensively studied in relation to carcinogenesis and malignancies [32-36]. 
PAFR-dependent pathways are activated during experimental tumoral growth, modifying the 
microenvironment and the phenotype of the tumoral macrophages in ways that favor tumoral 
growth [32]. The activated endothelium and/or cancer cells are thought to introduce PAF into 
the tumoral microenvironment [19, 33]. PAFR induces activation of G-proteins and tyrosine 
kinases, and the signals are transduced to downstream pathways, including NFκB, MAPKs, 
AKT, PI3, and Src [19, 35]. NFκB enhances tumoral metastasis and augments angiogenesis 
through activation of matrix metalloproteases (MMPs) and vascular endothelial growth factor 
[37-41]. PAF also directly activates endothelial cells, causes angiogenesis, and promotes 
vascular permeability leading to metastasis [35]. PAF/PAFR decreased PTEN activity, leading 
to phosphorylation of AKT and MAPKs. AKT plays a central role in various oncogenic 
processes including cellular growth, proliferation, motility, and epithelial mesenchymal 
transition (EMT) [38, 42]. PAF-induced activation of MAPKs, p38 and ERK1/2, occurred via 
MMP-dependent cleavage of heparin-binding epidermal growth factor and subsequent 
activation of the EGF receptor, increase proliferation [35, 43]. Thus, the PAF/PAFR pathway 
causes cellular growth, proliferation, motility, EMT, and angiogenesis in cancers. Furthermore, 
PAF can activate cancer cells and endothelial cells to amplify PAF production and PAFR 
expression on their membranes, in autocrine, endocrine, paracrine and juxtracrine interactions 
[19]. 
We thus assumed that the interaction between LPCAT1 with activated PAF/PAFR affects 
the cellular characteristics in OSCC-derived cells and examined the intracellular PAF 
concentration using ELISA and PAFR expression using immunoblot analysis. Consistent with 
our hypothesis, the PAF concentration decreased significantly in LPCAT1 knockdown cells 
compared with control cells, which suggested that intracellular PAF synthesis may be restricted 
due to down-regulation of LPCAT1. Moreover, immunoblot analysis showed that PAFR 
expression also was down-regulated markedly in LPCAT1 knockdown cells. These findings 
indicated that PAFR amplification weakened because of reduced PAF synthesis and stimulation 
in LPCAT1 knockdown cells; previous studies reported a similar tendency [6, 19]. Therefore, 
an intervention in PAF/PAFR pathway activation was possible in relation to overexpression of 
LPCAT1 and promotion of tumoral growth, invasiveness, and migration in OSCC-derived cell 
lines.  
In conclusion, our data indicated that LPCAT1 might be associated with tumoral 
progression and metastasis by synthesis of PAF and follow up-regulation of PAFR expression 
in OSCC. Although further studies are needed to understand the interaction between LPCAT1 
and the PAF/PAFR pathway and its functions in the cancer microenvironment, LPCAT1 is a 
potential biomarker of aggressive tumoral progression in human primary OSCCs. 
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Supporting Information 
Supplementary Fig. 1. Expression profiles of LPCAT2 in OSCC samples. (A) IHC of LPCAT2 on 
primary OSCC samples. Representative IHC results are shown for LPCAT2 protein in positive control 
(mouse pancreatic tissue) (a), normal oral tissue (b) and primary OSCCs (c). The original 
magnifications are 400×(a), 100×(b, c). There are only weak immunoreactions in both of normal 
oral tissues and primary OSCCs in comparison with positive control. (B) The status of LPCAT2 
protein expression in primary OSCCs (n=30) and the normal counterparts (n=30). IHC scores of 
LPCAT2 were calculated and its states are shown in the chart. The LPCAT2 IHC scores for normal 
oral tissues range from 1.83 to 22.33 and that of primary OSCCs range from 2.67 to 23.00. There is no 
significant difference between LPCAT2 protein expression levels in OSCCs and those in normal oral 
tissues (p=0.191). 
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